Grace Therapeutics
Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a late-stage biopharmaceutical company dedicated to the development of innovative drug delivery technologies aimed at improving treatments for rare and orphan diseases. With a focus on enhancing the performance of existing therapies, the company seeks to expedite the onset of action, augment efficacy, minimize side effects, and provide more user-friendly delivery options for patients.
Products & Team
GTx-104
GTx-104 is an intravenous infusion specifically designed for treating aneurysmal subarachnoid hemorrhage (aSAH), a rare and life-threatening condition characterized by bleeding on the surface of the brain. This product is currently in late-stage clinical development.
GTx-104 offers a promising solution by providing faster therapeutic action and better efficacy compared to traditional orally administered medications, thus potentially saving lives in acute settings.
These patients often experience limited treatment options, high healthcare costs, and inadequate therapeutic outcomes. Grace Therapeutics addresses these issues by enhancing drug effectiveness and reducing the burden of side effects.